<?xml version='1.0' encoding='utf-8'?>
<document id="24890600"><sentence text="Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro."><entity charOffset="45-58" id="DDI-PubMed.24890600.s1.e0" text="macrolactin A" /><entity charOffset="63-89" id="DDI-PubMed.24890600.s1.e1" text="7-O-succinyl macrolactin A" /><pair ddi="false" e1="DDI-PubMed.24890600.s1.e0" e2="DDI-PubMed.24890600.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24890600.s1.e0" e2="DDI-PubMed.24890600.s1.e1" /></sentence><sentence text="Macrolactin A (MA) and 7-O-succinyl macrolactin A (SMA), polyene macrolides containing a 24-membered lactone ring, show antibiotic effects superior to those of teicoplanin against vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus"><entity charOffset="0-13" id="DDI-PubMed.24890600.s2.e0" text="Macrolactin A" /><entity charOffset="23-49" id="DDI-PubMed.24890600.s2.e1" text="7-O-succinyl macrolactin A" /><entity charOffset="160-171" id="DDI-PubMed.24890600.s2.e2" text="teicoplanin" /><entity charOffset="180-190" id="DDI-PubMed.24890600.s2.e3" text="vancomycin" /><entity charOffset="217-228" id="DDI-PubMed.24890600.s2.e4" text="methicillin" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e0" e2="DDI-PubMed.24890600.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e0" e2="DDI-PubMed.24890600.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e0" e2="DDI-PubMed.24890600.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e0" e2="DDI-PubMed.24890600.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e0" e2="DDI-PubMed.24890600.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e1" e2="DDI-PubMed.24890600.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e1" e2="DDI-PubMed.24890600.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e1" e2="DDI-PubMed.24890600.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e1" e2="DDI-PubMed.24890600.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e2" e2="DDI-PubMed.24890600.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e2" e2="DDI-PubMed.24890600.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e2" e2="DDI-PubMed.24890600.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e3" e2="DDI-PubMed.24890600.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24890600.s2.e3" e2="DDI-PubMed.24890600.s2.e4" /></sentence><sentence text=" MA and SMA are currently being evaluated as antitumor agents in preclinical studies in Korea" /><sentence text=" We evaluated the potential of MA and SMA for the inhibition or induction of human liver cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGTs) in vitro to assess their safety as new molecular entities" /><sentence text=" We demonstrated that MA and SMA are potent competitive inhibitors of CYP2C9, with Ki values of 4" /><sentence text="06 μM and 10" /><sentence text="6 μM, respectively" /><sentence text=" MA and SMA also weakly inhibited UGT1A1 activity, with Ki values of 40" /><sentence text="1 μM and 65" /><sentence text="3 μM, respectively" /><sentence text=" However, these macrolactins showed no time-dependent inactivation of the nine CYPs studied"><entity charOffset="16-28" id="DDI-PubMed.24890600.s11.e0" text="macrolactins" /></sentence><sentence text=" In addition, MA and SMA did not induce CYP1A2, CYP2B6, or CYP3A4/5" /><sentence text=" On the basis of an in vitro-in vivo extrapolation, our data strongly suggested that MA and SMA are unlikely to cause clinically significant drug-drug interactions mediated via inhibition or induction of most of the CYPs involved in drug metabolism in vivo, except for the inhibition of CYP2C9 by MA" /><sentence text=" Similarly, MA and SMA are unlikely to inhibit the activity of UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7 enzymes in vivo" /><sentence text=" Although further investigations will be required to clarify the in vivo interactions of MA with CYP2C9-targeted drugs, our findings offer a clearer understanding and prediction of drug-drug interactions for the safe use of MA and SMA in clinical practice" /><sentence text=" " /></document>